Neurocrine Biosciences opened higher at $147.13, compared with its previous close of $146.38. In the last trading session, the stock traded between $145.22 and $149.25. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Neurocrine Biosciences is now worth
$ 139.93
giving a profit of
$ 39.93 (39.93%)
Note: Past profits do not guarantee future returns.
Rating from 24 Analysts
Today's Change
+$1.12 (+0.76%)
Day High
$149.25
Day Low
$145.22
Day Open
$147.13
Prev Close
$146.38
Volume
4,12,616
1W Return
2.89%
1M Return
6.67%
3M Return
-18.48%
6M Return
12.39%
1Y Return
6.86%
Market Cap ($ Mn)
14,993
PE Ratio
22.59
PB Ratio
4.24
PEG Ratio
1.73
ROE
17.00%
ROCE
17.84%
EPS (TTM)
$1.42
1 Week
2.89%
1 Month
6.67%
3 Months
-18.48%
6 Months
12.39%
9 Months
6.91%
Neurocrine Biosciences initiates Phase 2 trial for Alzheimer's drug NBI-1117567
Neurocrine Biosciences initiated Phase 2 trial of NBI-1117567. Target population includes adults with mild to moderate Alzheimer's disease. Compound is an orally administered M1/M4 selective muscarinic agonist. Evaluation focuses on adjunctive treatment for cognitive impairment.
10 days agoNeedham maintains Buy rating on Neurocrine Biosciences with $204 target
Needham analyst Ami Fadia reiterated a Buy rating on Neurocrine Biosciences. The price target was maintained at $204 per share. The rating action reflects unchanged valuation expectations for the company.
14 days agoNeurocrine stock falls 5% on Vykat XR safety alerts and death reports
Neurocrine Biosciences faces market pressure as safety concerns emerge around Vykat XR, with seven deaths and over 100 serious adverse events reported. Despite the negative sentiment, the drug contributed $54 million in Q2 2026 sales following the $2.9 billion Soleno acquisition. Pro forma sales for the quarter stood at $94 million, indicating strong underlying demand even as clinicians urge caution regarding patient selection and monitoring.
2mo agoNeurocrine Biosciences initiates Phase 1 trial for obesity drug NBIP-1968
Neurocrine Biosciences launched a Phase 1 trial for NBIP-1968, a GLP-1/GIP/glucagon triple agonist for obesity. The August 7, 2026 announcement highlights the company's focus on expanding its metabolic disease pipeline through advanced multi-target therapies.
2mo agoNeurocrine Biosciences Q2 Results: Adj. EPS beats estimates by 112%
Neurocrine Biosciences reported Q2 adjusted EPS of $2.85, beating the $1.34 estimate by 112.69% and rising 72.73% YoY. Sales reached $959.000 million, beating the $883.259M estimate and up 39.49% from $687.500M last year.
3mo agoNeurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer
Neurocrine Biosciences has appointed Samir Siddhanti as Chief Business Officer and a member of its executive Management Committee. Siddhanti will lead the enterprise growth strategy, overseeing business development, corporate strategy, alliance management, and program management. He previously served as Vice President, Business Development, and led the $2.9 billion acquisition of Soleno Therapeutics.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 |
An investment of $100 made 5 years ago in Neurocrine Biosciences is now worth
$ 139.93
giving a profit of
$ 39.93 (39.93%)
Note: Past profits do not guarantee future returns.
